In this MedPage Today interview with Jason Karlawish, MD, co-director of the Penn Memory Center at the University of Pennsylvania in Philadelphia and author of the new book, The Problem of Alzheimer’s: How Science, Culture, and Politics Turned a Rare Disease Into a Crisis and What We Can Do About It, the  biomarker “revolution” is discussed, along with the discovery of the idea of mild cognitive impairment.

US News & World Report recently published its state healthcare rankings, based on three measures: access to healthcare, quality of care, and overall health of the population, measuring rates of obesity, smoking, suicide, mental health, and mortality for adults and infants. At the top, Hawaii was the clear winner. At the bottom, Mississippi. Where does your state measure up in the rankings?

The IRS was kind enough to move the traditional tax deadline from April 15 to Monday, May 17, granting a bit of a reprieve for getting your financial affairs in order. Many physicians choose to handle their taxes themselves despite a good CPA paying for him/herself in the deductions and tax-savings strategies that they find for you. If you decide to go this route, here are some things you should be asking.

The numbers are staggering when it comes to heart disease, and it’s still the No. 1 killer in the US, according to the CDC. With 30.3 million American adults—12.1% of the adult population—diagnosed with heart disease, it’s certainly a struggle to keep it at bay, but there are preventive measures your patients can take. Here are five foods that represent a heart-healthy diet.

From the pages of Oncology Times comes the latest approvals, designations, and new indications from the U.S. Food and Drug Administration (FDA) for oncology drugs. Stories include new approvals in multiple myeloma, esophageal or gastroesophageal junction (GEJ) carcinoma, non-small cell lung cancer (NSCLC), anaplastic lymphoma, and more.

The FDA’s Oncologic Drugs Advisory Committee will hold a public meeting from April 27 to 29, 2020, to reevaluate six treatments that were previously granted accelerated approval and have since reported results that failed to verify clinical benefit. The six indications to be discussed include atezolizumab (two indications), pembrolizumab (three indications), and nivolumab (one indication).